No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

ReddyPort™ Elbow Non-Invasive Ventilation Product Receives CE Mark Approval

Editor: What To Know

  • The CE marking confirms that ReddyPort, a suite of solutions that promotes NIV success, and allows clinicians to perform procedures through the ventilation mask without interrupting therapeutic pressure meets the requirements of the European Medical Devices Directive (MDD).
  • “CE Mark is an important milestone and validation of our vision to make ReddyPort the standard of care for patients on NIV,”.
  • ReddyPort™ Elbow, in combination with ReddyPort™ NIV Maintenance Kit, allows the ability to clean and moisturize the patient’s mouth without mask removal.

ReddyPort, a medical technology company focused on solutions that enable better care experiences for patients on non-invasive ventilation (NIV), announced today that it has received Conformité Européene (CE) Mark approval for ReddyPort™ Elbow.

The CE marking confirms that ReddyPort, a suite of solutions that promotes NIV success, and allows clinicians to perform procedures through the ventilation mask without interrupting therapeutic pressure meets the requirements of the European Medical Devices Directive (MDD). This now allows ReddyPort to commercialize ReddyPort™ Elbow across the European Union and other CE Mark geographies.

“CE Mark is an important milestone and validation of our vision to make ReddyPort the standard of care for patients on NIV,” said Scott Bostick, chief executive officer of ReddyPort. CE Mark approval means we can help patients in Europe who struggle tolerating NIV therapy due to known issues while wearing the mask; dry-mouth, phlegm build-up, and difficulty communicating. ReddyPort™ Elbow and oral care products help improve tolerance, patient compliance, and comfort, leading to more successful NIV. Supporting a successful NIV is especially important now as clinicians need it most during the COVID-19 pandemic.”

NIV is the first line of therapy in respiratory insufficiency or failure, commonly seen with COPD, CHF, asthma, pneumonia or ARDS1. NIV intolerance can lead to failure and escalation of care with mechanical ventilation. ReddyPort products promote NIV success, by empowering clinicians and patients with simplified oral access without interrupting patient therapy.

ReddyPort features a proprietary elbow with self-sealing valve that provides access to the patient’s mouth. ReddyPort™ Elbow, in combination with ReddyPort™ NIV Maintenance Kit, allows the ability to clean and moisturize the patient’s mouth without mask removal. Oral hygiene is proven to help reduce risk of infection and improve patient satisfaction.


Reference:


1 Rochwerg B, Brochard L, Elliott MW, Hess D, et al. Official ERS/ATS Clinical Practice Guidelines: Noninvasive Ventilation for Acute Respiratory Failure. Eur Respir J. 2017: 31;50(2):1602426.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

VeraClinic: Pioneering Personal Transformation Through Hair Transplantation and Cosmetic Surgery in Turkey

As a testament to Turkey's legacy in the world of aesthetic medicine, VeraClinic invites you to discover the transformative power of our hair transplantation and cosmetic surgery services.

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy